HOXC10 and lung adenocarcinoma: Similar with the results obtained from GSE30219, HOXC10 predicted a poor overall survival (Figure 6F, HR = 1.4, 95%CI:1.11–1.77, p = 0.0043) and relapse free survival (Figure 6G, HR = 1.4, 95%CI:1.02–1.96, p = 0.0366) of lung adenocarcinoma, but not obvious in lung squamous cell carcinoma (Figures 6H,I).